acute low back pain (aLBP)
Conditions
Interventions
Control group:For acute low back pain conventional anti-inflammatory and analgesic treatment was given. One capsule of cileoxib (200mg per capsule National Drug Approval No. J20120063 Pfizer Pharmaceu
Group 2 hours of moxibustion:Based on the treatment of the control group the patients were given Bagua moxibustion therapy each session lasting 2 hours once every 2 days with 3 sessions as one course
The 30-minute moxibustion group:Based on the treatment of the control group the patients were given Bagua moxibustion therapy each session lasting 30 minutes once every two days with three sessions as
The 1-hour group during moxibustion:Based on the treatment of the control group the patients were given Bagua moxibustion therapy each session lasting 1 hour once every 2 days with 3 sessions as one c
Sponsors
Quanzhou Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Meet the above-mentioned diagnostic criteria of both Chinese and Western medicine; (2) Patients with low back pain lasting no more than 4 weeks aged between 18 and 70 with no gender restrictions; (3) Visual Analogue Scale (VAS) for pain (see attachment) =4 points with clear consciousness and stable vital signs; (4) No history of abdominal surgery or abnormal anatomical structure; (5) Informed consent and voluntary participation in this study with the informed consent form signed before treatment.
Exclusion criteria
Exclusion criteria: (1) Those who do not meet the diagnostic criteria and inclusion criteria; (2) Those who show symptoms such as lumbar fractures or dislocations through imaging examinations and require surgical treatment; (3) Patients with low back pain caused by other acute lesions such as renal artery stenosis acute kidney inflammation renal artery dissection and obstructive kidney stones; (4) Those with severe lesions in important organs; (5) Those with mental disorders who are unable to cooperate with treatment; (6) There are blisters ulcers or infections on the local skin of the abdomen; (7) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Muscle thickness under musculoskeletal ultrasound monitoring;Efficient; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scale before and after treatment;Roland morris disability questionnaire scores before and after treatment;Modified-Modified Schober Test before and after treatment; | — |
Countries
China
Contacts
Public ContactBuwanping
Quanzhou Medical College
Outcome results
None listed